Anti-Ebola GP (h-13F6)

Anti-Ebola GP [h-13F6], Recombinant, Fab fragment lambda, Human
Artikelnummer
ABAAb00790-10.6-BT
Verpackungseinheit
500 μg
Hersteller
Absolute Antibody

Verfügbarkeit: wird geladen...
Preis wird geladen...
CloneID: h-13F6

Heavy Chain modification: His-Tagged

Antigen Long Description: Murine 13F6 (IgG2a) was prepared by immunizing BALB/c mice with packaged Venezuelan equine encephalitis virus replicons encoding the GP from the Mayinga isolate of Ebola virus Zaire 1976. Murine 13F6 was deimmunized (to remove T-cell epitopes from the variable region sequences) and chimerized with human IgG1 constant regions to create h13F6.

Buffer Composition: PBS only.

Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Uniprot Accession No.: Q05320

Specificity Statement: h-13F6 binds specifically to the linear epitope ATQVEQHHRRTDNDSTA (aa 401–417) on Ebola Virus Zaire GP1. Proteolytic processing of GP results in two products, GP1 and membrane-bound GP2, that covalently associate to form a monomer of the GP spike found on the surfaces of virions. GP1 is also released from infected cells in a soluble form. The Ebola virus is of the family Filoviridae and causes acute hemorrhagic fever in humans and non-human primates. The membrane-anchored glycoprotein (GP) is the only viral protein known to be on the surfaces of virions and infected cells and is thought to be responsible for receptor binding and fusion of the virus with host cells.

Application Notes (Clone): h-13F6 binds to human FcγRI (CD64) and FcγRIII (CD16) (determined by SPR)and can confer in vitro ADCC activity and in vivo antitumor activity comparable to its fully murine parental mAb. h-13F6 also binds C1q (which is important for the first step in the classical complement cascade), and was determined by ELISA. h-13F6 also binds to mouse FcγRI, -II, and -III in vitro. h-13F6 has also been tested in lethal EBOV challenge mouse models where h-13F6 was shown to possess dose-dependent protectivity - equivalent protection between the original murine 13F6 and h-13F6. The antibody is unable to neutralize EBOV.
Mehr Informationen
Artikelnummer ABAAb00790-10.6-BT
Hersteller Absolute Antibody
Hersteller Artikelnummer Ab00790-10.6-BT
Verpackungseinheit 500 μg
Mengeneinheit STK
Reaktivität Virus
Klonalität Recombinant
Methode Immunoprecipitation, ELISA, Super-Resolution Microscopy
Isotyp Fab fragment lambda
Wirt Human
Produktinformation (PDF) Download
MSDS (PDF) Download